177Lu-PSMA-617 + 177Lu-PSMA-617
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Trial Timeline
Aug 15, 2025 → Mar 1, 2033
NCT ID
NCT06943495About 177Lu-PSMA-617 + 177Lu-PSMA-617
177Lu-PSMA-617 + 177Lu-PSMA-617 is a phase 1 stage product being developed by Novartis for Metastatic Castrate Resistant Prostate Cancer (mCRPC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06943495. Target conditions include Metastatic Castrate Resistant Prostate Cancer (mCRPC).
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castrate Resistant Prostate Cancer (mCRPC) were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06943495 | Phase 1 | Recruiting |
Competing Products
20 competing products in Metastatic Castrate Resistant Prostate Cancer (mCRPC)